Adaptimmune Therapeutics
Adaptimmune Therapeutics
Agent38Agent Readiness: 38/100. Below median. Measured by StartupHub.ai. Median 41.Biopharmaceutical company developing T-cell therapies for solid tumor cancers.
About
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel T-cell therapies for cancer. They utilize a proprietary T-cell receptor (TCR) platform to engineer T-cells that can identify and target cancer cells, aiming to significantly impact cancer treatment outcomes. Their pipeline includes therapies for various solid tumor types.
Key facts
At-a-glance profile data
- Website
- adaptimmune.com
- Headquarters
- Abingdon, United Kingdom
- Founded
- 2008
- Employees
- 191
- Total funding
- $107M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 24 Sept 2014 | Series A | $104M | New Enterprise Associates, OrbiMed |
| 25 Mar 2014 | Grant (prize money) | $3M | - |
Tech stack
Detected on adaptimmune.com, last scanned 4 Sept 2026. Run your own scan
- Frontend
- Bootstrap
- Analytics
- Google Analytics 4, LinkedIn Insight Tag
- Hosting
- AWS
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Adaptimmune Therapeutics raised?
Adaptimmune Therapeutics has raised a total of $107M in funding. The most recent round on record is Series A.
How many employees does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has approximately 191 people on record.